EP1809298A4 - Compositions pharmaceutiques neuroprotectrices contenant du spirostenol - Google Patents

Compositions pharmaceutiques neuroprotectrices contenant du spirostenol

Info

Publication number
EP1809298A4
EP1809298A4 EP05812949A EP05812949A EP1809298A4 EP 1809298 A4 EP1809298 A4 EP 1809298A4 EP 05812949 A EP05812949 A EP 05812949A EP 05812949 A EP05812949 A EP 05812949A EP 1809298 A4 EP1809298 A4 EP 1809298A4
Authority
EP
European Patent Office
Prior art keywords
spirostenol
neuroprotective
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05812949A
Other languages
German (de)
English (en)
Other versions
EP1809298A2 (fr
Inventor
Laurent Lecanu
Janet Greeson
Zhi-Xing Yao
Gary Teper
Vassilios Papadopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Georgetown University
Samaritan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/031,538 external-priority patent/US20060009433A1/en
Application filed by Georgetown University, Samaritan Pharmaceuticals Inc filed Critical Georgetown University
Publication of EP1809298A2 publication Critical patent/EP1809298A2/fr
Publication of EP1809298A4 publication Critical patent/EP1809298A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP05812949A 2004-10-14 2005-10-14 Compositions pharmaceutiques neuroprotectrices contenant du spirostenol Withdrawn EP1809298A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61869604P 2004-10-14 2004-10-14
US11/031,538 US20060009433A1 (en) 2003-03-14 2005-01-07 Neuroprotective spirostenol pharmaceutical compositions
PCT/US2005/037023 WO2006044665A2 (fr) 2004-10-14 2005-10-14 Compositions pharmaceutiques neuroprotectrices contenant du spirostenol

Publications (2)

Publication Number Publication Date
EP1809298A2 EP1809298A2 (fr) 2007-07-25
EP1809298A4 true EP1809298A4 (fr) 2008-06-18

Family

ID=36203560

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05812949A Withdrawn EP1809298A4 (fr) 2004-10-14 2005-10-14 Compositions pharmaceutiques neuroprotectrices contenant du spirostenol

Country Status (5)

Country Link
EP (1) EP1809298A4 (fr)
JP (1) JP2008516972A (fr)
AU (1) AU2005295617A1 (fr)
CA (1) CA2584333A1 (fr)
WO (1) WO2006044665A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603127A1 (fr) * 2005-04-01 2006-10-12 Samaritan Pharmaceuticals, Inc. Utilisation de spirostenols dans le traitement des troubles mitochondriaux
GB0619860D0 (en) * 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
JP6165323B2 (ja) * 2014-04-25 2017-07-19 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2024024395A1 (fr) * 2022-07-29 2024-02-01 国立大学法人富山大学 Composition pharmaceutique ou sous forme d'aliment et de boisson pour la prévention ou le traitement d'un trouble du nerf optique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011708A2 (fr) * 2000-08-04 2002-02-14 Symphar S.A. Procedes d'induction de la secretion d'apolipoproteine e
WO2003077869A2 (fr) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Compositions pharmaceutiques neuroprotectrices a base de spirostenol
WO2003086411A1 (fr) * 2002-04-15 2003-10-23 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Composes et techniques de preparation de carboxylate de diosgenine et d'un derive de succinate monoester de diosgenine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
TR200002774T2 (tr) * 1998-03-26 2001-06-21 Phytopharm Plc Alzheimer hastalığının tedavisi için steroit sapogenler ve bunların türevleri

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011708A2 (fr) * 2000-08-04 2002-02-14 Symphar S.A. Procedes d'induction de la secretion d'apolipoproteine e
WO2003077869A2 (fr) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Compositions pharmaceutiques neuroprotectrices a base de spirostenol
WO2003086411A1 (fr) * 2002-04-15 2003-10-23 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Composes et techniques de preparation de carboxylate de diosgenine et d'un derive de succinate monoester de diosgenine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOLDAMOVA R P, LEFTEROV I M, IKONOMOVIC M D, SKOKO J, LEFTEROV P I, ISANSKI B A, DEKOSKY S T, LAZO J S: "22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 15, 11 April 2003 (2003-04-11), pages 13244 - 13256, XP002476236 *
LECANU L ET AL: "Identification of naturally occurring spirostenols preventing beta-amyloid-induced neurotoxicity", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 69, no. 1, January 2004 (2004-01-01), pages 1 - 16, XP004484607, ISSN: 0039-128X *
LIU ZHONGRONG ET AL: "Preparation of carboxylate and monoester succinate derivatives of diosgenin and their bioactivities for treating and preventing cerebrovascular and cardiovascular diseases", HCAPLUS, 23 October 2003 (2003-10-23), XP002391897 *
YAO Z-X ET AL: "22R-Hydroxycholesterol Protects Neuronal Cells from Beta-Amyloid-Induced Cytotoxicity by Binding to Beta-Amyloid Peptide", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 83, 2002, pages 1110 - 1119, XP003015166, ISSN: 0022-3042 *

Also Published As

Publication number Publication date
AU2005295617A1 (en) 2006-04-27
WO2006044665A2 (fr) 2006-04-27
JP2008516972A (ja) 2008-05-22
EP1809298A2 (fr) 2007-07-25
CA2584333A1 (fr) 2006-04-27
WO2006044665A3 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL177480A0 (en) Pharmaceutical composition
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
IL188352A0 (en) Pharmaceutical compositions
IL183986A0 (en) Pharmaceutical compounds and compositions
GB0523810D0 (en) Pharmaceutical compositions
GB0405033D0 (en) Novel pharmaceutical compositions
GB0406378D0 (en) Novel pharmaceutical compositions
EP1805154A4 (fr) Compositions pharmaceutiques
GB0522045D0 (en) Pharmaceutical compositions
IL192091A0 (en) Pharmaceutical compositions
GB0406380D0 (en) Novel pharmaceutical compositions
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
EP1809298A4 (fr) Compositions pharmaceutiques neuroprotectrices contenant du spirostenol
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
EP1845944A4 (fr) Compositions pharmaceutiques
ZA200701931B (en) Pharmaceutical composition
EP1747205A4 (fr) Compositions pharmaceutiques
GB0502792D0 (en) Pharmaceutical compositions
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
GB0514259D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070504

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20070705

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/585 20060101ALI20070801BHEP

Ipc: A61K 31/58 20060101ALI20070801BHEP

Ipc: A61K 31/56 20060101ALI20070801BHEP

Ipc: A61K 31/59 20060101ALI20070801BHEP

Ipc: A01N 45/00 20060101AFI20070801BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20080429BHEP

Ipc: A61K 31/585 20060101ALI20080429BHEP

Ipc: A61K 31/58 20060101ALI20080429BHEP

Ipc: A61K 31/56 20060101ALI20080429BHEP

Ipc: A61K 31/59 20060101ALI20080429BHEP

Ipc: A01N 45/00 20060101AFI20070801BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080519

17Q First examination report despatched

Effective date: 20080819

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090303